Home › Funds › Menlo Ventures Management, L.P. › SYRE

Menlo Ventures Management, L.P. position in SYRE

SCRIBE THERAPEUTICS INC · Health Care

Menlo Ventures Management, L.P. reported holding 97,690 shares of SYRE (SCRIBE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$1.8M, representing 0.75% of its reported portfolio and ranking #3 among its reported holdings. Menlo Ventures Management, L.P. first reported this position in Q3 2026.

Latest position (Q3 2026)97.69K sh
Reported value held$1.80M
Portfolio Weight0.75%
First reportedQ3 2026
Last changeNew
Updated2026-11-07

Last updated: 2026-11-07 · Source: SEC EDGAR Form 13F-HR

How Menlo Ventures Management, L.P.'s SYRE position evolved

Menlo Ventures Management, L.P. first disclosed a stake in SYRE in Q3 2026 at 97,690 shares (US$1.8M).

Quarter by quarter

QuarterSharesValueChange
Q3 2026 97.69K $1.80M New

About SYRE and 13F data

SYRE (SCRIBE THERAPEUTICS INC) is a Health Care company. 71 other funds we track also report a position in SYRE — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$383.5M), RTW INVESTMENTS, LP (US$377.5M), Paradigm Biocapital Advisors LP (US$341.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SYRE

All SYRE fund holders →

FAQ

How long has Menlo Ventures Management, L.P. held SYRE?

Menlo Ventures Management, L.P. has disclosed SYRE holdings in 1 of the last 1 reported quarters, going back to Q3 2026.

What is Menlo Ventures Management, L.P.'s current position in SYRE?

As of Q3 2026, Menlo Ventures Management, L.P. holds 97.69K shares of SYRE (SCRIBE THERAPEUTICS INC), valued at $1.80M, representing 0.75% of its reported portfolio and ranking #3.

Has Menlo Ventures Management, L.P. been buying or selling SYRE?

In the latest 13F filing (Q3 2026), Menlo Ventures Management, L.P. newly opened its position in SYRE.

Which other funds hold SYRE?

Other major institutional holders of SYRE include PERCEPTIVE ADVISORS LLC, RTW INVESTMENTS, LP, Paradigm Biocapital Advisors LP, among 71 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.